March 27, 2025 7:56am

Sector cowers as algorithms and electronic trading are flexing their “rules”

I their some upside available (?), the aftermarket appeared downtrodden

News: Trouble in CRISPR Therapeutics (CRSP) land as Chief Operating Officer, Julianne Bruno steps down to pursue external opportunities, effective as of April 11, 2025.

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief …

Never leave an investor uninform

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Wednesday’s night’s … RegMed Investors (RMi) Closing Bell: Occam’s razor … https://www.regmedinvestors.com/articles/13855

 

Thursday: The pre-open Dow futures are UP +0.08 or (36 points), the S&P futures are DOWN -0.09% or (-5 points) and the Nasdaq futures are DOWN -0.19% or (-38 points)

  • Stock futures are barely, mixed and fluctuating with little changed Thursday,3/27,
  • European stocks were sharply lower.
  • Asia-Pacific markets traded mixed

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Indexes dived on Wednesday, led lower by tech, as pressure on the tariff front mounted.
  • Wednesday: The Dow closed DOWN -132.71 points or -0.31%, the S&P closed DOWN -64.45 points or -1.12% while the Nasdaq closed DOWN -372.84 points or -2.04%

Economic Data Docket: Initial jobless claims, GDP (second revision), Advanced U.S. trade balance in goods - Feb., Advanced retail inventories, Advanced wholesale inventories, Pending home sales- Feb.

  • Friday - Personal Consumption Expenditures Index (PCE) and core PCE and University of Michigan's Consumer Sentiment Index

 

Q1/25:  March sessions with 9 positive and 10 negative closes

  • February – 1 holiday, 11 negative and 8 positive closes
  • January – 2 holidays, 1 market close, 10 negative and 10 positive closes

Q4/24:

  • December 1 holiday, 15 negative and 5 positive closes
  • November 10 negative and 9 positive closes
  • October: 8 positive and 15 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the …  econs, it is still a mix of ups, downs and just uncertainty.

 

The BOTTOM LINE: the last full week …

  • the 4th of March …Monday closed positive followed by negative closes on Tuesday and Wednesday …
  • Friday and Thursday closed negative after Wednesday closed positive, Tuesday closed negative following Monday’s positive close
  • A positive Friday sector close following Thursday’s negative close after 2 positive (Wednesday & Tuesday) closes following Monday’s negative close.
  • The previous Friday, 3/7 – the 5th NEGATIVE session in the week intermingled by 1 POSITIVE (Wednesday) close in a new month of March … so, what moves stock pricing

As I have written, “uncle algo and his trading dwarfs” will determine the heights or lows of share pricing”

Tears for a company and its employees: Elevation Oncology Inc. is setting aside its lead cancer drug and making widespread layoffs.

  • EO-3021, which Elevation was working on to treat advanced, nonresectable or metastatic gastric and gastroesophageal junction cancers. This was Elevation’s sole clinical-stage program.
  • As a result, Elevation (Nasdaq: ELEV) is making major cuts to its workforce. The company plans to lay off around 70% of its workforce. At the end of 2024 Elevation reported 34 full-time employees, implying around 24 people will lose their jobs. Among those leaving is medical chief Valerie Malyvanh Jansen, who plans to support the company in a consulting capacity.

 

March to date:

  • 3/26 – Wednesday closed negative with 3 positive, 28 negative and 4 flats
  • 3/25 - Tuesday closed negative with 7 positive, 25 negative and 3 flats
  • 3/24 - Monday closed positive with 31 positive, 3 negative and 1 flat
  • 3/21 – Friday closed positive with 17 positive, 16 negative and 2 flats
  • 3/20 – Thursday closed negative with 10 positive, 23 negative and 2 flats
  • 3/19 - Wednesday closed positive with 25 positive, 8 negative and 2 flats
  • 3/18 - Tuesday closed negative with 7 positive, 27 negative and 1 flat
  • 3/17 – Monday closed positive with 24 positive, 10 negative and 1 flat
  • 3/14 – Friday closed positive with 20 positive, 13 negative and 2 flats
  • 3/13 - Thursday closed negative with 4 positive, 30 negative and 1 flat
  • 3/12 – Wednesday closed positive with 25 positive, 9 negative and1 flat
  • 3/11 - Tuesday closed positive with 23 positive, 11 negative and 1 flat
  • 3/10 – Monday closed negative with 3 positive, 31 negative and 1 flat
  • 3/7 – Friday closed negative with 14 positive, 17 negative and 4 flats
  • 3/6 – Thursday closed negative with 16 positive, 18 negative and 1 flat
  • 3/5 – Wednesday closed positive with 25 positive, 9 negative and 1 flat
  • 3 /4 – Tuesday closed negative with 15 positive, 18 negative and 2 flats
  • 3/3 – Monday closed negative with 2 positive, 31 negative and 2 flats

 

Reiterating, “I think it's important just to take a step back, focus on the fundamentals, be selective. I mean, this has definitely been a “sucky” January and February from a stock-picker standpoint given the up/downs. And so, I am relatively neutral across today/Friday’s equity strategy.

  • Reiterating, “Take the emotion out of the sector, think of the reality of the “plays” that exist of who’s really buying.”

It’s all but OVER … earnings season “sparked” a quarterly life crisis…

  • Think about it; one of the biggest problems with the cell and gene therapy sector’s share pricing is …  99% of them have no earnings! If rates are higher for longer, that means that sector companies will continue to struggle or be unable to raise capital and therefore be subject.

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.